Compugen (NASDAQ: CGEN) reported Q3 EPS of ($0.19), in-line with the analyst estimate of ($0.19).

Recent highlights:

• Granted patent for COM701 under United States Patent and Trademark Office Moonshot Program.
• Entered into a new research collaboration agreement with Mount Sinai Hospital in New York under the direction of Dr. Miriam Merad, a world leader in myeloid biology and a member of Compugen\'s scientific advisory board (SAB).
• Extended research collaboration with Johns Hopkins University School of Medicine under the direction of Prof. Drew Pardoll, chairman of the Company\'s SAB.
• Presented CGEN-15032, a newly-disclosed novel myeloid and epithelial immuno-oncology target, in an oral and a poster presentation at the 3rd annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference which took place September 6‑9, 2017 in Mainz/Frankfurt, Germany.
• Entered into a process development and manufacturing service agreement with Bayer Healthcare LLC to produce COM902 for future use in clinical trials.

For earnings history and earnings-related data on Compugen (CGEN) click here.